English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Most of the HIV-1 vaccines under development contain multiple viral genes or proteins. As a result, many vaccinerecipients react positive in licensed HIV-1 detection assays. This will have negative impact on future efficacy trials of prophylactic HIV vaccines that require early detection of intercurrent HIV infections. It will also exclude all vaccinees from blood/plasma donations, and may contribute to other social harms. Therefore, it is important to design new strategies for vaccine trial participants that will clearly discriminate between vaccine-induced antibodies and true HIV-1 infection. We identified new HIV-1 epitopes that: 1) Do not contain important neutralizing or CTL epitopes, and can be omitted from future HIV vaccine candidates, 2) Recognized by antibodies from early HIV infected individuals, 3) Highly conserved among HIV-1 clades and subtypes. Using Phage Display libraries constructed from whole HIV-1 genome, combined with panning over antibodies from early seroconvertors, we identified new immunodominant epitopes, in the gp41 intracytoplasmic tail and in p6, which conform to the above criteria.

retrovirology

HIV-1 Infections During Vaccine Trials: Identifying New Peptides for Differential Diagnosis of HIV-1 Infections in the Face of Vaccine-generated Antibodies